NICE, UK's health watchdog, says sight-saving drugs, Lucentis and Macugen, are too expensive for general use on the NHS in England and Wales.
NICE says Lucentis should only be used once patients had already lost the sight in one eye and Macugen should not be used.
Health campaigners said the ruling would condemn 20,000 people a year to blindness. A final ruling on the drugs is expected by the end of September. Read more...
Has NICE put a price tag on people's health like the US economists have done? Read an earlier posting "How much is your life worth?" on June 11, 2007.
No comments:
Post a Comment